JPMorgan cuts Alnylam stock price target on Amvuttra forecast

JPMorgan reduced its price target for Alnylam Pharmaceuticals (ALNY) to $254 from $369, citing lowered Amvuttra revenue forecasts. The stock has fallen 61% YTD. The firm expects 2027 guidance in February. Alnylam announced a $1B stock repurchase program. Multiple analysts have adjusted targets downward, citing execution risks and slower demand.

Original reporting
Published Nov 18, 2026, 12:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 12:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$ALNY
Bearish
medium confidence
Mentioned
$ALNY
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ALNYBearishMed
01

Why it matters

The forecast reduction (2026-2030 revenue down 2% to 21%) and the PT cut from $369 to $254 are concrete valuation inputs that can drive incremental positioning, especially given the stock’s large YTD drawdown.

02

Market read

A specific sell-side forecast reset for Amvuttra plus a large PT reduction provides a fresh catalyst for traders managing biotech valuation and near-term expectation risk.

03

What to watch

The article also mentions a $1B repurchase program and a shift in when 2027 guidance will be provided, which could support sentiment and reduce near-term information risk.

Relevance 7/10Novelty 6/10Timing: today’s analyst note and PT reset

Background

The piece centers on JPMorgan’s model review for Alnylam’s Amvuttra and expectation resets tied to early launch demand composition and Part B reimbursement under 340b.

Company-level read

Ticker impact

$ALNYBearishMedium confidence
Context

JPMorgan cut Alnylam’s Amvuttra revenue forecasts for 2026-2030 and lowered its price target to $254 while keeping an Overweight rating.

Expected impact

Likely downward pressure as the market reprices Amvuttra demand and reimbursement uncertainty reflected in the forecast reset.

Evidence & confidence

The article discloses a specific analyst model change (revenue forecast reduction) plus a large PT cut, alongside expectation resets tied to launch momentum and 340b reimbursement changes.

Market effects

Biopharma investors may further scrutinize launch momentum and reimbursement dynamics for specialty therapies, affecting sentiment across similar commercial-stage names.

Primarily US biotech sentiment, with read-through to NASDAQ biotech risk appetite.

Limited direct global impact beyond broader risk appetite for commercial-stage rare-disease and specialty pharma.

Counterpoint

Despite the PT cut, JPMorgan maintained Overweight, implying the valuation still offers upside if 2027 guidance and demand normalize.

Key entities

  • Alnylam Pharmaceuticals

    NASDAQ-listed biotech subject of JPMorgan’s Amvuttra forecast review and price-target cut.

  • Amvuttra

    Alnylam therapy whose revenue forecasts were reduced due to revised launch and reimbursement assumptions.

  • JPMorgan

    Brokerage that lowered the price target and adjusted forecast assumptions while keeping Overweight.

Related articles

$ALNYHighAI 8/10

Why Alnylam Pharmaceuticals (ALNY) Stock Is Up Today

Alnylam Pharmaceuticals (ALNY) stock rose 6.9% after the company shared positive long-term data for AMVUTTRA, reinforcing its cardiovascular benefits. The company also reiterated 2026 guidance and authorized a $1 billion share repurchase program, signaling confidence. Insider and institutional trading activity was noted, with mixed positions.

$ALNYMedAI 9/10

Alnylam's AMVUTTRA Shows Sustained Benefits Through Five Years In ATTR-CM

Alnylam Pharmaceuticals (ALNY) reported five-year data from the HELIOS-B study, showing that early treatment with AMVUTTRA (vutrisiran) in ATTR-CM patients led to better long-term outcomes, including a 48% reduction in mortality and cardiovascular events in the monotherapy group. The study also showed improved quality of life and stability in cardiac biomarkers. The safety profile remained consistent. The findings were presented at the American Heart Association Scientific Sessions 2026.